Dr Rosalind Wilson appointed as Chief Medical Officer

Announcement highlights:

- Highly experienced global oncology drug development leader with >30 years' experience
- Proven track record advancing therapies from early development through to approval and launch
- Appointment strengthens Prescient's clinical and strategic capabilities at a key growth stage
- CEO, James McDonnell will hold an online investor briefing on Monday, 29th June at 11am (AEST). Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

MELBOURNE Australia, 11 June 2026: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to announce the appointment of Dr Rosalind Wilson as Chief Medical Officer (CMO) effective 13 July 2026.

Dr Wilson is a highly accomplished pharmaceutical and biotechnology executive with more than 30 years' experience spanning clinical development, regulatory strategy and executive leadership. Her appointment further strengthens Prescient's leadership team as the Company advances its pipeline through key stages of clinical development.

The Company's current CMO, Dr Marissa Lim, has decided to step-back from full-time employment and move into semi-retirement, following a significant contribution to the progression of Prescient's clinical programs.

Dr Wilson has held senior global leadership roles including Global Head of Drug Development at Telix Pharmaceuticals, CEO of ASX-listed Factor Therapeutics, and has previously served as Chief Medical Officer for oncology-focused biotechnology companies.

Earlier in her career, she led the global development and launch strategy for pertuzumab (Perjeta) at Roche, contributing to accelerating approval timelines and landmark regulatory precedents in breast cancer.

Her experience spans the full drug development continuum - from Phase 1 studies through to regulatory submission and commercial launch - across multiple oncology indications.

As CMO, Dr Wilson will lead Prescient's clinical development strategy and execution, including advancement of PTX-100 in its Phase 2 CTCL study and progression of the broader pipeline.

"We are delighted to welcome Dr Rosalind Wilson to Prescient. Ros brings an exceptional track record in oncology drug development and executive leadership, with deep experience advancing therapies through to approval and commercialisation. Her expertise will be instrumental as we progress our pipeline and deliver on our next phase of growth," said James McDonnell, CEO.

"We thank Dr Marissa Lim for her valuable contributions to Prescient and wish her well in her next chapter" said James McDonnell, CEO.

"I am excited to join Prescient at such an important stage in its development. The Company's pipeline represents a compelling opportunity to deliver meaningful benefit to patients with cancer. I look

forward to working with the team to advance these programs and unlock their full potential," said Dr Rosalind Wilson

JOIN A BRIEFING

Join CEO, James McDonnell, for an online investor briefing on Monday, 29th of June 2026 at 11am (AEST). Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

- ENDS -

The Disclosure Committee of the Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries
James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

About Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGTase-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is understood to be the only GGTase-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a

method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.